Publication | Closed Access

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

MedicineImmunologyColorectal CancerPathologyImmune Checkpoint InhibitorRefractory Solid TumorsAdvanced Colorectal CancerOncologyRadiation OncologyPhase 1Cancer Growth